Human NOV/CCN3 Antibody

Catalog # Availability Size / Price Qty
MAB1640-SP
MAB1640-500
MAB1640-100
Product Details
Citations (4)
FAQs
Supplemental Products
Reviews (4)

Human NOV/CCN3 Antibody Summary

Species Reactivity
Human
Specificity
Detects human NOV/CCN3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, this antibody does not cross-react with recombinant mouse NOV, recombinant human (rh) CTGF, or rhWISP-1.
Source
Monoclonal Mouse IgG1 Clone # 209808
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
Mouse myeloma cell line NS0-derived recombinant human NOV/CCN3
Thr32-Met357
Accession # P48745
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
Recombinant Human NOV/CCN3 (Catalog # 1640-NV)
under non-reducing conditions only

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: NOV/CCN3

NOV, also called CCN3, is one of six CCN (CYR61/CTGF/NOV) secreted proteins which share a common multimodular organization (1 - 4). NOV/CCN3 contains an N-terminal IGFBP domain that appears to be non-functional and a vWF type C and thrombospondin type I domain which mediate oligomerization and matrix interactions, respectively (1, 2). The C-terminal cysteine knot domain interacts with several partners, including the matrix protein fibulin 1C (5), Notch-1 (6), and CCN2, with which it may heterodimerize (2). NOV/CCN3 also interacts with the gap junction protein Connexin43 and mediates suppression of proliferation (7). It also binds the calcium binding protein S100A4 and promotes calcium channel activation (8). The 357 amino acid (aa), 44 kDa human NOV/CCN3 shares 80% aa identity with mouse, rat and dog NOV/CCN3, and 78% aa identity with cow NOV/CCN3. NOV/CCN3 also shows 38 - 50% aa identity with other family members including WISP proteins, except for WISP-2/CCN5 which lacks the cysteine knot (1). NOV/CCN3 is widely expressed developmentally, especially in muscle, endothelium, nervous system, adrenal cortex and chondrocytes (1 - 4). In transformed cells, a 32 kDa N-terminally truncated form lacks the signal sequence is localized to the nucleus. Truncation allows a C-terminal nuclear localization sequence to be active (9). Nuclear NOV/CCN3 acts as a transcriptional repressor but promotes proliferation, presumably by interfering with growth control (9). Full length NOV/CCN3 is a secreted matricellular protein which inhibits cell growth. Interaction of NOV/CCN3 with integrins alpha v beta 3 and  alpha 5 beta 1 mediates endothelial cell adhesion, chemotaxis, and promotes angiogenesis (10, 11). Over-expression of NOV/CCN3 downregulates myogenic genes such as MyoD (12).

References
  1. Perbal, B. (2004) Lancet 363:62.
  2. Perbal, B. (2006) Cell Commun. Signal. 4:3.
  3. Martinerie, C. et al. (1994) Oncogene 9:2729.
  4. Snaith, M.R. et al. (1996) Genomics 38:425.
  5. Perbal, B. et al. (1999) Proc. Natl. Acad. Sci. USA 96:869.
  6. Sakamoto, K. et al. (2002) J. Biol. Chem. 277:29399.
  7. Fu, C.T. et al. (2004) J. Biol. Chem. 279:36943.
  8. Li, C.L. et al. (2002) Mol. Pathol. 55:250.
  9. Planque, N. et al. (2006) J. Cell. Biochem. 99:105.
  10. Lin, C.G. et al. (2003) J. Biol. Chem. 278:24200.
  11. Lin, C.G. et al. (2003) J. Biol. Chem. 280:8229.
  12. Calhabeu, F. et al. (2006) Exp. Cell. Res. 312:1876.
Long Name
Nephroblastoma Overexpressed Gene
Entrez Gene IDs
4856 (Human); 18133 (Mouse)
Alternate Names
CCN family member 3; CCN3; CCN3IGF-binding protein 9; IBP-9; IGFBP-9; IGFBP9novH; Insulin-like growth factor-binding protein 9; nephroblastoma overexpressed gene; Nephroblastoma-overexpressed gene protein homolog; NOV; NOVH; protein NOV homolog

Product Datasheets

You must select a language.

x

Citations for Human NOV/CCN3 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

4 Citations: Showing 1 - 4
Filter your results:

Filter by:

  1. Anti-CTGF single-chain variable fragment dimers inhibit human airway smooth muscle (ASM) cell proliferation by down-regulating p-Akt and p-mTOR levels.
    Authors: Gao W, Cai L, Xu X, Fan J, Xue X, Yan X, Qu Q, Wang X, Zhang C, Wu G
    PLoS ONE, 2014-12-05;9(12):e113980.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: ELISA Development
  2. Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis
    Authors: Bruce L. Riser, Narasimharao Bhagavathula, Patricia Perone, Kendra Garchow, Yiru Xu, Gary J. Fisher et al.
    Journal of Cell Communication and Signaling
  3. CCN3/CCN2 regulation and the fibrosis of diabetic renal disease
    Authors: Bruce L. Riser, Feridoon Najmabadi, Bernard Perbal, Jo Ann Rambow, Melisa L. Riser, Ernest Sukowski et al.
    Journal of Cell Communication and Signaling
  4. CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease.
    Authors: Riser BL, Najmabadi F, Perbal B, Peterson DR, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC
    Am. J. Pathol., 2009-04-09;174(5):1725-34.
    Species: Rat
    Sample Types: Cell Culture Supernates, Cell Lysates
    Applications: ELISA Development, Western Blot

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human NOV/CCN3 Antibody

Average Rating: 3.8 (Based on 4 Reviews)

5 Star
0%
4 Star
75%
3 Star
25%
2 Star
0%
1 Star
0%

Have you used Human NOV/CCN3 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human NOV/CCN3 Antibody
By Anonymous on 01/14/2021
Application: Microarrays Sample Tested: EDTA Plasma Species: Human

Human NOV/CCN3 Antibody
By Anonymous on 11/14/2018
Application: Microarrays Sample Tested: EDTA Plasma Species: Human

Human NOV/CCN3 Antibody
By Anonymous on 11/10/2018
Application: ELISA Sample Tested: Plasma Species: Human

Human NOV/CCN3 Antibody
By Anonymous on 10/09/2018
Application: MiAr Sample Tested: EDTA Plasma Species: Human